US Bancorp
CTXR icon

US Bancorp’s Citius Pharmaceuticals CTXR Stock Holding History

US Bancorp’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-80
Closed -$1.58K – 4105
2022
Q4 		$1.58K Sell
80
-400
-83% -$10.9K ﹤0.01% 3835
2022
Q3 		$15K Hold
480
– – ﹤0.01% 3173
2022
Q2 		$11K Hold
480
– – ﹤0.01% 3332
2022
Q1 		$21K Hold
480
– – ﹤0.01% 3040
2021
Q4 		$18K Hold
480
– – ﹤0.01% 3155
2021
Q3 		$24K Buy
480
+40
+9% +$2.01K ﹤0.01% 3030
2021
Q2 		$38K Hold
440
– – ﹤0.01% 2797
2021
Q1 		$20K Buy
440
+40
+10% +$1.59K ﹤0.01% 3023
2020
Q4 		$10K Hold
400
– – ﹤0.01% 3170
2020
Q3 		$10K Buy
+400
New +$11.3K ﹤0.01% 3071

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

US Bancorp's CTXR Position: Q1 2023 in Review

US Bancorp sold out of Citius Pharmaceuticals (CTXR) in Q1 2023, closing a stake of 80 shares — an estimated $1.58K sold.

US Bancorp first reported a position in CTXR in Q3 2020 and held it in 10 quarters. The position peaked at $38K in Q2 2021. 55 funds tracked by Wall St. Rank hold CTXR as of Q1 2023.

  • US Bancorp reported no remaining Citius Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • US Bancorp sold 80 Citius Pharmaceuticals shares in Q1 2023, an estimated $1.58K.
  • US Bancorp first reported a position in Citius Pharmaceuticals in Q3 2020 and held it in 10 quarters.
  • US Bancorp's Citius Pharmaceuticals position peaked at $38K in Q2 2021.
  • 55 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2023.

Based on US Bancorp's 13F filing for Q1 2023, filed 9 May 2023.